MA53236A - Traitement des malignités des lymphocytes b - Google Patents
Traitement des malignités des lymphocytes bInfo
- Publication number
- MA53236A MA53236A MA053236A MA53236A MA53236A MA 53236 A MA53236 A MA 53236A MA 053236 A MA053236 A MA 053236A MA 53236 A MA53236 A MA 53236A MA 53236 A MA53236 A MA 53236A
- Authority
- MA
- Morocco
- Prior art keywords
- malignities
- lymphocyte
- treatment
- lymphocyte malignities
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718929P | 2018-08-14 | 2018-08-14 | |
| US201862775797P | 2018-12-05 | 2018-12-05 | |
| US201962836511P | 2019-04-19 | 2019-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53236A true MA53236A (fr) | 2021-06-23 |
Family
ID=69525845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053236A MA53236A (fr) | 2018-08-14 | 2019-08-13 | Traitement des malignités des lymphocytes b |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210299134A1 (fr) |
| EP (1) | EP3836935A4 (fr) |
| JP (1) | JP2021534115A (fr) |
| KR (1) | KR20210043635A (fr) |
| CN (1) | CN112888441A (fr) |
| AU (1) | AU2019321432A1 (fr) |
| BR (1) | BR112021002760A2 (fr) |
| CA (1) | CA3109184A1 (fr) |
| IL (1) | IL280726A (fr) |
| MA (1) | MA53236A (fr) |
| MX (1) | MX2021001606A (fr) |
| SG (1) | SG11202101450VA (fr) |
| TW (1) | TW202021591A (fr) |
| WO (1) | WO2020036999A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013024907A2 (pt) | 2011-03-28 | 2016-12-20 | Mei Pharma Inc | composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k |
| KR20200009088A (ko) | 2017-05-23 | 2020-01-29 | 메이 파마, 아이엔씨. | 병용 요법 |
| AU2018318129A1 (en) | 2017-08-14 | 2020-03-26 | Mei Pharma, Inc. | Combination therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014500275A (ja) * | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
| BR112013024907A2 (pt) * | 2011-03-28 | 2016-12-20 | Mei Pharma Inc | composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k |
| WO2016049214A1 (fr) * | 2014-09-23 | 2016-03-31 | Genentech, Inc. | Procédé d'utilisation d'immunoconjugués anti-cd79b |
| WO2017007658A1 (fr) * | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | Combinaison à médiation immunitaire pour le traitement du cancer |
| AU2016312514A1 (en) * | 2015-08-24 | 2018-03-15 | Epizyme, Inc. | Method for treating cancer |
| WO2018017708A1 (fr) * | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Lymphocytes car-t cd229 et leurs procédés d'utilisation |
| EP3515414B1 (fr) * | 2016-09-19 | 2022-11-30 | MEI Pharma, Inc. | Polythérapie |
| WO2018060833A1 (fr) * | 2016-09-27 | 2018-04-05 | Novartis Ag | Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha |
| WO2018082444A1 (fr) * | 2016-11-02 | 2018-05-11 | 叶宝欢 | Composé de pyrazolopyrimidine en tant qu'inhibiteur de pi3k et son utilisation |
| AU2018318129A1 (en) * | 2017-08-14 | 2020-03-26 | Mei Pharma, Inc. | Combination therapy |
-
2019
- 2019-08-13 AU AU2019321432A patent/AU2019321432A1/en not_active Abandoned
- 2019-08-13 EP EP19849451.0A patent/EP3836935A4/fr not_active Withdrawn
- 2019-08-13 CN CN201980067607.2A patent/CN112888441A/zh active Pending
- 2019-08-13 JP JP2021506716A patent/JP2021534115A/ja active Pending
- 2019-08-13 MA MA053236A patent/MA53236A/fr unknown
- 2019-08-13 MX MX2021001606A patent/MX2021001606A/es unknown
- 2019-08-13 WO PCT/US2019/046411 patent/WO2020036999A1/fr unknown
- 2019-08-13 US US17/268,052 patent/US20210299134A1/en not_active Abandoned
- 2019-08-13 CA CA3109184A patent/CA3109184A1/fr active Pending
- 2019-08-13 BR BR112021002760-2A patent/BR112021002760A2/pt unknown
- 2019-08-13 SG SG11202101450VA patent/SG11202101450VA/en unknown
- 2019-08-13 KR KR1020217007417A patent/KR20210043635A/ko unknown
- 2019-08-14 TW TW108128967A patent/TW202021591A/zh unknown
-
2021
- 2021-02-08 IL IL280726A patent/IL280726A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202021591A (zh) | 2020-06-16 |
| US20210299134A1 (en) | 2021-09-30 |
| EP3836935A1 (fr) | 2021-06-23 |
| CN112888441A (zh) | 2021-06-01 |
| CA3109184A1 (fr) | 2020-02-20 |
| KR20210043635A (ko) | 2021-04-21 |
| SG11202101450VA (en) | 2021-03-30 |
| IL280726A (en) | 2021-03-25 |
| MX2021001606A (es) | 2021-04-19 |
| AU2019321432A1 (en) | 2021-03-25 |
| WO2020036999A1 (fr) | 2020-02-20 |
| EP3836935A4 (fr) | 2022-09-14 |
| JP2021534115A (ja) | 2021-12-09 |
| BR112021002760A2 (pt) | 2021-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45192A (fr) | Traitement d'association | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA52219A (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA47820A (fr) | Traitement de la glycogénose de type iii | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA53236A (fr) | Traitement des malignités des lymphocytes b | |
| MA51525A (fr) | Traitement de minéraux | |
| MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
| MA53741A (fr) | Procédés de traitement de troubles myéloprolifératifs | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
| MA53127A (fr) | Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA52627A (fr) | Traitement du cancer | |
| MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques |